All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Daratumumab, lenalidomide and dexamethasone granted positive opinion by EMA CHMP
During the October meeting of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), a positive opinion was granted to daratumumab (D) plus lenalidomide (R) and dexamethasone (d, D-Rd) for the treatment of adult patients with newly diagnosed (ND) multiple myeloma (MM, NDMM) who were ineligible for transplant. The CHMP recommended that the marketing authorization for daratumumab should be amended.1,2 Dara-Rd was previously approved by the United States (U.S.) Food & Drug Administration (FDA) in the same setting.3
Current EMA approvals for D
In Europe, D is currently approved;1
- In combination with bortezomib (V), melphalan (M) and prednisone (P, VMP) for adult patients with NDMM who are ineligible for transplant
- In combination with Rd, or Vd, for adult patients with MM who have received ≥ one prior therapy
- As monotherapy for adult patients with relapsed/refractory MM who have previously received treatment with a proteasome inhibitor and an immunomodulatory agent, and who have experienced disease progression from last therapy
MAIA4
The EMA CHMP positive opinion is based on the results from MAIA, an international phase III trial comparing D-Rd to Rd in patients with NDMM who are ineligible for transplant. The interim results were presented at the 60th American Society of Hematology Exposition and Meeting, 2018, and were published in The New England Journal of Medicine in May 2019.
As of 24th September 2018, D-Rd provided a 44% reduction in the risk of progression or death compared to Rd alone, with measurable residual disease (MRD) rates that were three-fold higher.
- D-Rd (n= 368) vs Rd (n= 369)
- Median follow-up: 28 months
- PFS (D-Rd vs Rd): Not reached (NR) vs 31.9 months (95% CI, 49.5–61.3)
- Hazard ratio for disease progression or death in D-Rd arm vs Rd arm: 0.56
- 95% CI: 0.43–0.73, p< 0.001
- MRD negativity (D-Rd vs Rd): 24% vs 7%, p< 0.001
- Main treatment emergent adverse events grade III–IV (D-Rd vs Rd):
- Neutropenia: 50% vs 35%
- Anemia: 12% vs 20%
- Lymphopenia: 15% vs 11%
- Pneumonia: 14% vs 8%
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?